

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	Not Yet Assigned
Filing Date	03/03/04
First Named Inventor	Ron L. HALE
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	00038.03CON

I hereby appoint:

Practitioners at Customer Number  
**OR**  
 Practitioner(s) named below:

37485

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The above-mentioned Customer Number.  
**OR**  
 The address associated with Customer Number:


--

<input type="checkbox"/> Firm or Individual Name			
Address			
Address			
City	State	Zip	
Country			
Telephone	Fax		

I am the:

Applicant/Inventor.  
 Assignee of record of the entire interest. See 37 CFR 3.71.  
*Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).*

### SIGNATURE of Applicant or Assignee of Record

Name	Alexza Molecular Delivery Corporation		
Signature			
Date	March 3, 2004	Telephone	650.687.3900

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple

\*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN**
Docket Number (Optional)  
00038.03CONApplicant, Patentee, or Identifier: Ron L. HALE, et al.Application or Patent No.: Not Yet AssignedFiled or Issued: March 3, 2004Title: DELIVERY OF RIZATRIPTAN OR ZOLMITRIPTAN THROUGH AN INHALATION ROUTE

I hereby state that I am

the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Alexza Molecular Delivery CorporationADDRESS OF SMALL BUSINESS CONCERN 1001 E. Meadow Circle, Palo Alto, California 94303

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 37 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

the specification filed herewith with title as listed above.

the application identified above.

the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

no such person, concern, or organization exists.

each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance

NAME OF PERSON SIGNING Elaine C. Stracker J.D., Ph.D.TITLE OF PERSON IF OTHER THAN OWNER V.P. Intellectual PropertyADDRESS OF PERSON SIGNING 1001 E. Meadow Circle, Palo Alto, California 94303SIGNATURE Elaine C. Stracker DATE March 3, 2004

**DECLARATION FOR UTILITY PATENT APPLICATION**

AS BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:

Our residences, post office addresses, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: DELIVERY OF RIZATRIPTAN OR ZOLMITRIPTAN THROUGH AN INHALATION ROUTE, the specification of which is attached hereto unless the following box is checked:

was filed on May 22, 2002 as United States Application Serial No. 10/155,621.

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing	Priority Claimed?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:


Application Serial No.	Filing Date
60/294,203	May 24, 2001
60/317,479	September 5, 2001
60/332,280	November 21, 2001
60/336,218	October 30, 2001

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior


United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

8-26-02   
Date Name: Ron L. HALE  
Residence: 17085 Skyline Boulevard, Woodside, California 94062  
Citizenship: United States of America  
Post Office Address: 17085 Skyline Boulevard, Woodside, California 94062

8/26/02   
Date Name: Joshua D. RABINOWITZ  
Residence: 750 N. Shoreline Boulevard, #50, Mountain View, California 94043  
Citizenship: United States of America  
Post Office Address: 750 N. Shoreline Boulevard, #50, Mountain View, California 94043

8/26/02   
Date Name: Dennis W. SOLAS  
Residence: 22 Sequoia Way, San Francisco, California 94127  
Citizenship: United States of America  
Post Office Address: 22 Sequoia Way, San Francisco, California 94127

8/23/02   
Date Name: Alejandro C. ZAFFARONI  
Residence: 1 Faxon Forest, Atherton, California 94027  
Citizenship: United States of America  
Post Office Address: 1 Faxon Forest, Atherton, California 94027

## ASSIGNMENT JOINT

THIS ASSIGNMENT, by Ron L. HALE, Joshua D. RABINOWITZ, Dennis W. SOLAS and Alejandro C. ZAFFARONI (hereinafter referred to as the assignors), residing at 17085 Skyline Boulevard, Woodside, California 94062; 750 N. Shoreline Boulevard, #50, Mountain View, California 94043; 22 Sequoia Way, San Francisco, California 94127 and 1 Faxon Forest, Atherton, California 94027, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in DELIVERY OF RIZATRIPTAN OR ZOLMITRIPTAN THROUGH AN INHALATION ROUTE, set forth in an application for Letters Patent of the United States, bearing Serial No. 10/155,621 and filed on May 22, 2002; and

WHEREAS, ALEXZA Molecular Delivery Corporation, a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 1001 East Meadow Circle, Palo Alto, California 94303 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

<u>8-26-02</u>	<u>Ron L. Hale</u> Ron L. HALE
<u>8/26/02</u>	<u>Joshua D. Rabinowitz</u> Joshua D. RABINOWITZ
<u>8/26/02</u>	<u>Dennis W. Solas</u> Dennis W. SOLAS
<u>8/23/02</u>	<u>Alejandro C. Zaffaroni</u> Alejandro C. ZAFFARONI